Cargando…

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related diseases remains high. Anticoagulation aims to prevent thrombus extension and reduce the risk of recurrent events, particularly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ageno, Walter, Mantovani, Lorenzo G, Haas, Sylvia, Kreutz, Reinhold, Haupt, Verena, Schneider, Jonas, Turpie, Alexander GG
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Original Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120724/ https://www.ncbi.nlm.nih.gov/pubmed/25093014 http://dx.doi.org/10.1186/1477-9560-12-16

Ejemplares similares

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis
por: Cano, Stefan, et al.
Publicado: (2018)

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies
por: Haas, Sylvia, et al.
Publicado: (2021)

Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA
por: Ageno, Walter, et al.
Publicado: (2019)

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
por: Turpie, Alexander GG, et al.
Publicado: (2012)

Predictive value of venous thromboembolism (VTE)‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients with VTE: results of the XALIA study
por: Klok, Frederikus A., et al.
Publicado: (2018)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions
por: Kreutz, Reinhold, et al.
Publicado: (2016)

The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery – subgroup analyses from 17,701 patients in the XAMOS study
por: Haas, Sylvia, et al.
Publicado: (2016)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
por: Haas, Sylvia, et al.
Publicado: (2014)

Portal Vein Thrombosis in Decompensated Cirrhosis: Rationale for Treatment
por: Senzolo, Marco, et al.
Publicado: (2019)

Timing of anticoagulation for the management of portal vein thrombosis in liver cirrhosis
por: Valeriani, Emanuele, et al.
Publicado: (2023)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette‐based survey
por: Riva, Nicoletta, et al.
Publicado: (2020)

Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study
por: Min, Seung-Kee, et al.
Publicado: (2022)

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients
por: Kwong, Louis, et al.
Publicado: (2015)

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
por: Camm, A. John, et al.
Publicado: (2020)

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study
por: Ageno, Walter, et al.
Publicado: (2022)

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban
por: Yang, Hyeyoung, et al.
Publicado: (2016)

COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation
por: Miesbach, Wolfgang, et al.
Publicado: (2020)

Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J’xactly) study
por: Okumura, Yasuo, et al.
Publicado: (2018)

Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis
por: Candeloro, Matteo, et al.
Publicado: (2022)

Splanchnic Vein Thrombosis: Current Perspectives
por: Valeriani, Emanuele, et al.
Publicado: (2019)

Decreased Rivaroxaban Levels in a Patient with Cerebral Vein Thrombosis Receiving Phenytoin
por: Becerra, Ana F., et al.
Publicado: (2017)

A Case of Renal Vein Thrombosis Associated With COVID-19 Treated With Rivaroxaban
por: Asleson, Louise, et al.
Publicado: (2022)

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
por: Turpie, Alexander G.G., et al.
Publicado: (2017)

The Need to Anticoagulate Patients With Splenic Vein Thrombosis
por: Benjamin, Clara, et al.
Publicado: (2022)

Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions
por: Riva, Nicoletta, et al.
Publicado: (2020)

Single-drug approach with rivaroxaban: A case of successful anticoagulation against cancer-associated thrombosis
por: Shioyama, Wataru, et al.
Publicado: (2019)

A Case of Isolated Unilateral Right Renal Vein Thrombosis Associated with Bilateral Pulmonary Embolism Treated with Rivaroxaban a Direct-Acting Oral Anticoagulant
por: Matta, Anthony, et al.
Publicado: (2019)

Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment
por: Koitabashi, Norimichi, et al.
Publicado: (2015)

Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban
por: Naito, Tomoyuki, et al.
Publicado: (2018)

Clinical significance of the rivaroxaban–dronedarone interaction: insights from physiologically based pharmacokinetic modelling
por: Hügl, Burkhard, et al.
Publicado: (2023)

Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis
por: Suda, Tsuyoshi, et al.
Publicado: (2020)

Poor response to rivaroxaban in nephrotic syndrome with acute deep vein thrombosis: A case report
por: Li, Yan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_df23qkiaclun527f4rg67mnkp2